Richard A. Heyman

机构：Araim Pharmaceuticals (United States)

发表论文 133 篇 · 总被引 21280 次 · h-index 60

代表论文

• Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c (2004 · Journal of Clinical Investigation · 被引 1385)
• Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle (2004 · Proceedings of the National Academy of Sciences · 被引 689)
• ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment (2012 · Cancer Research · 被引 667)
• Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists (2004 · Arteriosclerosis Thrombosis and Vascular Biology · 被引 284)
• Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts (2015 · Journal of Medicinal Chemistry · 被引 251)
• Regulation of PPARγ coactivator 1α (PGC-1α) signaling by an estrogen-related receptor α (ERRα) ligand (2004 · Proceedings of the National Academy of Sciences · 被引 197)